Beyond weight loss: Addressing critical unmet needs in obesity treatment

Highly effective anti-obesity medications have transformed treatment, producing levels of weight loss that were previously difficult to achieve with medication. Yet important unmet needs remain. Tolerability, adherence, access, patient burden and the challenge of maintaining weight loss can all influence long-term outcomes. 

In Beyond weight loss: Addressing critical unmet needs in obesity treatment, we examine how the obesity treatment landscape is evolving and what drug development sponsors should consider as the field moves toward durable, patient-centered disease management. 

Inside the article, you'll discover:

• How GLP-1 receptor agonists and emerging multi-pathway therapies are reshaping obesity treatment

• Why maintaining high-quality weight loss requires attention to body composition, skeletal muscle, bone mass and physical function

• Key challenges related to tolerability, adherence, affordability, access and treatment burden

• Opportunities to improve convenience and durability through oral formulations, less frequent dosing, sequential therapies and complementary mechanisms of action

• Why future therapies may be evaluated on cardiometabolic health, long-term outcomes and sustained benefits beyond weight reduction

The article also considers how obesity phenotypes, comorbidities, previous treatment response, body composition and metabolic risk may inform more personalized treatment approaches. Together, these considerations highlight the need to balance efficacy with tolerability, durability, convenience, affordability and improved obesity-related health outcomes.